157 related articles for article (PubMed ID: 29982514)
1. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.
Bollestad M; Grude N; Solhaug S; Raffelsberger N; Handal N; Nilsen HS; Romstad MR; Emmert A; Tveten Y; Søraas A; Jenum PA; Jenum S; Møller-Stray J; Weme ET; Lindbaek M; Simonsen GS;
J Antimicrob Chemother; 2018 Sep; 73(9):2503-2509. PubMed ID: 29982514
[TBL] [Abstract][Full Text] [Related]
2. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
3. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Syre H; Hetland MAK; Bernhoff E; Bollestad M; Grude N; Simonsen GS; Löhr IH
APMIS; 2020 Mar; 128(3):232-241. PubMed ID: 31755584
[TBL] [Abstract][Full Text] [Related]
4. Treatment duration of pivmecillinam in men, non-pregnant and pregnant women for community-acquired urinary tract infections caused by Escherichia coli: a retrospective Danish cohort study.
Boel JB; Jansåker F; Hertz FB; Hansen KH; Thønnings S; Frimodt-Møller N; Knudsen JD
J Antimicrob Chemother; 2019 Sep; 74(9):2767-2773. PubMed ID: 31098630
[TBL] [Abstract][Full Text] [Related]
5. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kalin M; Giske CG
Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
8. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Søraas A; Sundsfjord A; Jørgensen SB; Liestøl K; Jenum PA
PLoS One; 2014; 9(1):e85889. PubMed ID: 24454943
[TBL] [Abstract][Full Text] [Related]
9. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project.
Ferry SA; Holm SE; Stenlund H; Lundholm R; Monsen TJ
Scand J Prim Health Care; 2007 Mar; 25(1):49-57. PubMed ID: 17354160
[TBL] [Abstract][Full Text] [Related]
10. Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Cho SY; Choi SM; Park SH; Lee DG; Choi JH; Yoo JH
Korean J Intern Med; 2016 Jan; 31(1):156-61. PubMed ID: 26767869
[TBL] [Abstract][Full Text] [Related]
11. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial.
Vik I; Bollestad M; Grude N; Bærheim A; Damsgaard E; Neumark T; Bjerrum L; Cordoba G; Olsen IC; Lindbæk M
PLoS Med; 2018 May; 15(5):e1002569. PubMed ID: 29763434
[TBL] [Abstract][Full Text] [Related]
12. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol.
Jansåker F; Frimodt-Møller N; Bjerrum L; Dahl Knudsen J
BMC Infect Dis; 2016 Dec; 16(1):727. PubMed ID: 27905884
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
[TBL] [Abstract][Full Text] [Related]
15. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
Auer S; Wojna A; Hell M
Antimicrob Agents Chemother; 2010 Sep; 54(9):4006-8. PubMed ID: 20585127
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological factors associated with ESBL- and non ESBL-producing E. coli causing urinary tract infection in general practice.
Hertz FB; Schønning K; Rasmussen SC; Littauer P; Knudsen JD; Løbner-Olesen A; Frimodt-Møller N
Infect Dis (Lond); 2016; 48(3):241-5. PubMed ID: 26523346
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study.
Esteve-Palau E; Solande G; Sánchez F; Sorlí L; Montero M; Güerri R; Villar J; Grau S; Horcajada JP
J Infect; 2015 Dec; 71(6):667-74. PubMed ID: 26380898
[TBL] [Abstract][Full Text] [Related]
18. Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial.
Bjerrum L; Gahrn-Hansen B; Grinsted P
Scand J Prim Health Care; 2009; 27(1):6-11. PubMed ID: 18991182
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for community acquired urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing
Zhu FH; Rodado MP; Asmar BI; Salimnia H; Thomas R; Abdel-Haq N
Infect Dis (Lond); 2019; 51(11-12):802-809. PubMed ID: 31429616
[No Abstract] [Full Text] [Related]
20. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
